Nextcell Pharma Ab

NextCell Pharma AB received a US patent for its MSC Prediction Algorithm, which predicts the efficacy of mesenchymal stromal cell therapy in individual patients with autoimmune diseases.

Diamyd Medical has raised approximately SEK 267 million ($25.5 million) through rights issues and a directed issue, receiving an additional SEK 1.6 million beyond previously announced figures.